Bone turnover markers are used both in diagnosis and in therapeutic monitoring of Paget's disease. We studied 10 patients with poliostotic Paget's disease treated with risendronate (30 mg/day for 2 months)in order to evaluate the usefullness of seruma CTx, serum NTx and urine NTx as parameters of bone resorption in the management of therapy. The bone turnover markers were evaluated at baseline and 30 days after therapy. A significant reduction in the markers of bone resorption and neoformation was demonstrated. Our study shows that serum CTx is a sensitive marker of bone resorption in the management of bisphosphonate therapy in Paget's disease.
Markers of bone resorption in bisphosphonate therapy of Paget’s disease
CACACE, ENRICO;RUGGIERO, VALERIA;
2004-01-01
Abstract
Bone turnover markers are used both in diagnosis and in therapeutic monitoring of Paget's disease. We studied 10 patients with poliostotic Paget's disease treated with risendronate (30 mg/day for 2 months)in order to evaluate the usefullness of seruma CTx, serum NTx and urine NTx as parameters of bone resorption in the management of therapy. The bone turnover markers were evaluated at baseline and 30 days after therapy. A significant reduction in the markers of bone resorption and neoformation was demonstrated. Our study shows that serum CTx is a sensitive marker of bone resorption in the management of bisphosphonate therapy in Paget's disease.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
